SPIN·DETECTOR

How the coverage framed it

Coverage of this story was largely uniform across all three outlets, with a bias spread of just 0.0 points and no meaningful ideological divide in framing. All headlines treated the story as straightforward pharmaceutical trial news, relying on factual, clinical language. CNBC described the drug regimen as one that "boosts weight loss in mid-stage trial," Reuters used competitive benchmarking language — "tops Zepbound in weight-loss trial" — and MarketWatch offered the most specific figure, noting people lost "up to 23% of their weight." The only minor distinction worth noting is that MarketWatch was the sole outlet to introduce a cautionary element, adding "But there were more side effects," which provides readers a more complete picture of the trial results. This slight addition of balance, rather than reflecting ideological bias, simply reflects a more comprehensive summary of the underlying data.